Benzimidazole TNF Trimer Binders for Specific Signaling Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional antagonists of TNF superfamily members, such as anti-TNFα antibodies and soluble receptor fusion proteins, are macromolecular and lack specificity in modulating TNFα signaling, leading to inefficiencies in treating conditions like rheumatoid arthritis and autoimmune diseases.
Innovation Solution
Development of small molecular entities (SMEs) that bind to the homotrimeric form of TNFα, inducing conformational changes and stabilizing the trimer to modulate receptor signaling, along with assays to identify these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antagonists (anti-TNFα antibodies, soluble receptor fusion proteins) are used to inhibit TNFα signaling, then the therapeutic effect is achieved, but the specificity and efficiency are reduced due to macromolecular structure
Solution Approach 1:
The patent changes the molecular size parameter from macromolecular (antibodies, fusion proteins) to small molecular entities (SMEs), fundamentally altering the therapeutic agent's properties to achieve both effectiveness and specificity
Solution Approach 2:
The invention extracts the essential therapeutic function from complex macromolecules and implements it through simpler SMEs that specifically bind to and stabilize the TNFα homotrimer, removing unnecessary complexity while retaining therapeutic efficacy
2Reliability
If macromolecular antagonists are used to block TNFα-receptor binding, then TNFα signaling is inhibited, but the compounds lack stability and specificity
Solution Approach 1:
The patent changes the stability parameter by designing SMEs with appropriate molecular weight ranges (50-1000 Da) that provide optimal stability for binding to TNFα homotrimer while maintaining drug-like properties
Solution Approach 2:
The invention employs composite molecular structures containing benzimidazole moieties combined with various substituents (aromatic rings, heterocycles, alkyl chains) to achieve both stability and specific binding to TNFα
3Adaptability or versatility
If conventional antagonists are administered to treat TNFα-mediated conditions, then therapeutic coverage is achieved, but off-target effects occur due to reduced specificity
Solution Approach 1:
The patent applies local quality by designing SMEs with specific functional groups (benzimidazole core with tailored substituents) that provide precise local interaction with TNFα binding sites, enhancing specificity while maintaining therapeutic coverage
Solution Approach 2:
The invention segments the therapeutic function into discrete molecular components, with the benzimidazole moiety providing specific TNFα binding and substituent groups fine-tuning selectivity, allowing targeted action without off-target effects
Data Source
AI summary
It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. Anew assay for identifying compounds with this mechanism of action is also disclosed.